Seer, which is developing next-generation proteome analysis tests for biomedical research, raised $175 million by offering 9.2 million shares at $19, above the range of $16 to $18. The company offered 0.4 million more shares than anticipated. At pricing, Seer commands a fully diluted market value of $1.3 billion.
Seer plans to list on the Nasdaq under the symbol SEER. J.P. Morgan, Morgan Stanley, BofA Securities and Cowen acted as lead managers on the deal.
